Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Saved in:
| Title: | Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. |
|---|---|
| Authors: | Hamlin PA; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Flinn IW; Center for Blood Cancer, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Wagner-Johnston N; Division of Oncology, Washington University, St. Louis, Missouri., Burger JA; Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas., Coffey GP; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California., Conley PB; Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California., Michelson G; Clinical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Leeds JM; Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Der K; Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California., Kim Y; Regulatory Affairs, Portola Pharmaceuticals, Inc., South San Francisco, California., Sabalvaro-Torres A; Clinical Operations, Portola Pharmaceuticals, Inc., South San Francisco, California., Birrell M; Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Pandey A; Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Curnutte JT; Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California., Patel MR; Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida. |
| Source: | American journal of hematology [Am J Hematol] 2019 Apr; Vol. 94 (4), pp. E90-E93. Date of Electronic Publication: 2019 Jan 08. |
| Publication Type: | Clinical Trial, Phase I; Letter; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1096-8652 |
|---|---|
| DOI: | 10.1002/ajh.25387 |
